Carilion Materials Management

Manufacturer Details

There are currently no manufacturer details available.

Share This Page

Carilion Materials Management Drugs

  • Isradipine Capsule [Carilion Materials Management]

    Isradipine

    Isradipine Capsule [Carilion Materials Management]

    The dosage of isradipine should be individualized. The recommended initial dose of isradipine is 2.5 mg b.i.d. alone or in combination with a thiazide diuretic. An antihypertensive response usually occurs within 2-3 hours. Maximal response may require 2-4 weeks. If a satisfactory reduction in blood pressure does not occur after this period, the dose may be adjusted in increments of 5 mg/day at 2-4 week intervals up to a maximum of 20 mg/day. Most patients, however, show no additional response to doses above 10 mg/day, and adverse effects are increased in frequency above 10 mg/day.

    The bioavailability of isradipine (increased AUC) is increased in elderly patients (above 65 years of age), patients with hepatic functional impairment, and patients with mild renal impairment. Ordinarily, the starting dose should still be 2.5 mg b.i.d. in these patients.

  • Acetaminophen And Diphenhydramine Hcl Tablet [Carilion Materials Management]

    Acetaminophen And Diphenhydramine Hcl

    Acetaminophen And Diphenhydramine Hcl Tablet [Carilion Materials Management]

    adults and children 12 years or over:

    take 2 captabs at bedtine if needed do not take more than directed

    childrens under 12 years do not use

  • Nystatin Tablet, Film Coated [Carilion Materials Management]

    Nystatin

    Nystatin Tablet, Film Coated [Carilion Materials Management]

    The usual therapeutic dosage is one to two tablets (500,000 to 1,000,000 units nystatin) three times daily. Treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse.

  • Atorvastatin Calcium Tablet, Film Coated [Carilion Materials Management]

    Atorvastatin Calcium

    Atorvastatin Calcium Tablet, Film Coated [Carilion Materials Management]

    2.1 Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia ( Types IIa and IIb)  Fredrickson

    The recommended starting dose of atorvastatin calcium tablets is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin calcium tablets is 10 to 80 mg once daily. Atorvastatin calcium tablets can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin calcium tablets should be individualized according to patient characteristics such as goal of therapy and response (see current ). After initiation and/or upon titration of atorvastatin calcium tablets, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.    NCEP Guidelines

    2.2  Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 to 17 years of age)  

    The recommended starting dose of atorvastatin calcium tablets is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy [see current , , and ]. Adjustments should be made at intervals of 4 weeks or more. NCEP Pediatric Panel GuidelinesClinical Pharmacology (12)Indications and Usage (1.2)

    2.3 Homozygous Familial Hypercholesterolemia  

    The dosage of atorvastatin calcium tablets in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin calcium tablets should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.

    2.4 Concomitant Lipid-Lowering Therapy 

    Atorvastatin calcium tablets may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see , ]. Warnings and Precautions, Skeletal Muscle (5.1)Drug Interactions (7)

    2.5 Dosage in Patients With Renal Impairment

    Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary [see , ]. Warnings and Precautions, Skeletal Muscle (5.1)Clinical Pharmacology, Pharmacokinetics (12.3)

    2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors 

    In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), therapy with atorvastatin should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary employed.  In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with atorvastatin should be limited to  20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin is employed. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, therapy with atorvastatin should be limited to 40 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin is employed [see , ]. Warnings and Precautions,Skeletal Muscle (5.1)Drug Interactions (7)

  • Fluvastatin Sodium
    Fluvastatin Sodium (Fluvastatin) Capsule [Carilion Materials Management]

    Fluvastatin Sodium

    Fluvastatin Sodium (Fluvastatin) Capsule [Carilion Materials Management]

    2.1 General Dosing Information

    Dose range: 20 mg to 80 mg/day.

    Fluvastatin capsules can be administered orally as a single dose, with or without food.

    Do not open fluvastatin capsules prior to administration.

    Do not take two fluvastatin 40 mg capsules at one time.

    Since the maximal effect of a given dose is seen within 4 weeks, periodic lipid determinations should be performed at this time and dosage adjusted according to the patient’s response to therapy and established treatment guidelines.

    For patients requiring LDL-C reduction to a goal of ≥ 25%, the recommended starting dose is 40 mg as one capsule in the evening, or 80 mg in divided doses of the 40 mg capsule given twice daily. For patients requiring LDL-C reduction to a goal of < 25% a starting dose of 20 mg may be used.

    2.2 Adult Patients with Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia

    Adult patients can be started on fluvastatin capsules. The recommended starting dose for fluvastatin capsules is one 40 mg capsule in the evening, or one fluvastatin 40 mg capsule twice daily. Do not take two fluvastatin 40 mg capsules at one time.

    2.3 Pediatric Patients (10 to 16 Years of Age) with Heterozygous Familial Hypercholesterolemia

    The recommended starting dose is one 20 mg fluvastatin capsule. Dose adjustments, up to a maximum daily dose administered as fluvastatin capsules 40 mg twice daily should be made at 6 week intervals. Doses should be individualized according to the goal of therapy. [See NCEP Pediatric Panel Guidelines and .] Clinical Studies (14)1

    National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. 89(3):495-501. 1992. 1Pediatrics.

    2.4 Use with Cyclosporine

    Do not exceed a dose of 20 mg BID fluvastatin capsules in patients taking cyclosporine .  [see ] Drug Interactions (7.1)

    2.5 Use with Fluconazole

    Do not exceed a dose of 20 mg BID fluvastatin capsules in patients taking fluconazole . [see ] Drug Interactions (7.2)

  • Ketorolac Tromethamine Tablet, Film Coated [Carilion Materials Management]

    Ketorolac Tromethamine

    Ketorolac Tromethamine Tablet, Film Coated [Carilion Materials Management]

    Carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. In adults, the combined duration of use of IV or IM dosing of ketorolac tromethamine and ketorolac tromethamine tablets is not to exceed 5 days. In adults, the use of ketorolac tromethamine tablets is only indicated as continuation therapy to IV or IM dosing of ketorolac tromethamine.

    Transition from IV or IM dosing of ketorolac tromethamine (single- or multiple-dose) to multiple-dose ketorolac tromethamine tablets:

    Patients age 17 to 64: 20 mg PO once followed by 10 mg q4 to 6 hours prn not > 40 mg/day

    Patients age ≥ 65, renally impaired, and/or weight < 50 kg (110 lbs): 10 mg PO once followed by 10 mg q4 to 6 hours prn not> 40 mg/day

    Note:

    should be given . Oral formulationnotas an initial dose

    for the individual patient. Use minimum effective dose

    Do of 4 to 6 hours. not shorten dosing interval

    the combined duration of use of IV or IM dosing of ketorolac tromethamine and ketorolac tromethamine tablets is not to exceed 5 days. Total duration of treatment in adult patients:

    The following table summarizes ketorolac tromethamine tablet dosing instructions in terms of age group:

    Table 4: Summary of Dosing Instructions Patient Population Ketorolac Tromethamine Tablets (following IV or IM dosing of ketorolac tromethamine) Age < 17 years Oral not approved Adult Age 17 to 64 years 20 mg once, then 10 mg q4 to 6 hours prn not > 40 mg/day Adult Age ≥ 65 years, renally impaired, and/or weight < 50 kg 10 mg once, then 10 mg q4 to 6 hours prn not > 40 mg/day
  • Diltiazem Hydrochloride Capsule, Extended Release [Carilion Materials Management]

    Diltiazem Hydrochloride

    Diltiazem Hydrochloride Capsule, Extended Release [Carilion Materials Management]

    Dosage needs to be adjusted by titration to individual patient needs. When used as monotherapy, usual starting doses are 120 to 240 mg once daily. Maximum antihypertensive effect is usually observed by 14 days of chronic therapy; therefore, dosage adjustments should be scheduled accordingly. The usual dosage range studied in clinical trials was 120 to 540 mg once daily. Current clinical experience with 540 mg dose is limited; however, the dose may be increased to 540 mg once daily. Hypertension.

    Dosages for the treatment of angina should be adjusted to each patient's needs, starting with a dose of 120 mg to 180 mg once daily. Individual patients may respond to higher doses of up to 540 mg once daily. When necessary, titration should be carried out over 7 to 14 days. Angina.

    Concomitant use with Other Cardiovascular Agents.

    May be taken as required to abort acute anginal attacks during diltiazem hydrochloride therapy. 1.Sublingual Nitroglycerin (NTG).

    . Diltiazem hydrochloride may be safely co-administered with short- and long-acting nitrates. 2Prophylactic Nitrate Therapy.

    (See and .) 3.Beta-blockersWARNINGSPRECAUTIONS

    Diltiazem hydrochloride has an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of diltiazem hydrochloride or the concomitant antihypertensives may need to be adjusted when adding one to the other. 4.Antihypertensives.

    Hypertensive or anginal patients who are treated with other formulations of diltiazem can safely be switched to diltiazem hydrochloride extended-release capsules at the nearest equivalent total daily dose. Subsequent titration to higher or lower doses may, however, be necessary and should be initiated as clinically indicated.

    Sprinkling the Capsule Contents on Food

    Diltiazem hydrochloride extended-release capsules may also be administered by carefully opening the capsule and sprinkling the capsule contents on a spoonful of applesauce. The applesauce should be swallowed immediately without chewing and followed with a glass of cool water to ensure complete swallowing of the capsule contents. The applesauce should not be hot, and it should be soft enough to be swallowed without chewing. Any capsule contents/applesauce mixture should be used immediately and not stored for future use. Subdividing the contents of a diltiazem hydrochloride extended-release capsules is not recommended.

  • Ery-tab (Erythromycin) Tablet, Delayed Release [Carilion Materials Management]

    Ery-tab

    Ery-tab (Erythromycin) Tablet, Delayed Release [Carilion Materials Management]

    In most patients, ERY-TAB (erythromycin delayed-release tablets) are well absorbed and may be dosed orally without regard to meals. However, optimal blood levels are obtained when ERY-TAB 250 mg, ERY-TAB 333 mg or ERY-TAB 500 mg tablets are given in the fasting state (at least 1/2 hour and preferably 2 hours before meals). ®®®®

    Adults

    The usual dose is 250 mg four times daily in equally spaced doses. The 333 mg tablet is recommended if dosage is desired every 8 hours. If twice-a-day dosage is desired, the recommended dose is 500 mg every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the infection. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.

    Children

    Age, weight, and severity of the infection are important factors in determining the proper dosage. The usual dosage is 30 to 50 mg/kg/day, in equally divided doses. For more severe infections, this dose may be doubled but should not exceed 4 g per day.

    In the treatment of streptococcal infections of the upper respiratory tract (e.g., tonsillitis or pharyngitis), the therapeutic dosage of erythromycin should be administered for at least ten days.

    The American Heart Association suggests a dosage of 250 mg of erythromycin orally, twice a day in long-term prophylaxis of streptococcal upper respiratory tract infections for the prevention of recurring attacks of rheumatic fever in patients allergic to penicillin and sulfonamides. 4

    Conjunctivitis of the Newborn Caused by Chlamydia trachomatis

    Oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 2 weeks. 4

    Pneumonia of Infancy Caused by Chlamydia trachomatis

    Although the optimal duration of therapy has not been established, the recommended therapy is oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 3 weeks.

    Urogenital Infections During Pregnancy Due to Chlamydia trachomatis

    Although the optimal dose and duration of therapy have not been established, the suggested treatment is 500 mg of erythromycin by mouth four times a day or two erythromycin 333 mg tablets orally every 8 hours on an empty stomach for at least 7 days. For women who cannot tolerate this regimen, a decreased dose of one erythromycin 500 mg tablet orally every 12 hours, one 333 mg tablet orally every 8 hours or 250 mg by mouth four times a day should be used for at least 14 days. 6

    For adults with uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis, when tetracycline is contraindicated or not tolerated

    500 mg of erythromycin by mouth four times a day or two 333 mg tablets orally every 8 hours for at least 7 days. 6

    For patients with nongonococcal urethritis caused by Ureaplasma urealyticum when tetracycline is contraindicated or not tolerated

    500 mg of erythromycin by mouth four times a day or two 333 mg tablets orally every 8 hours for at least seven days. 6

    Primary Syphilis

    30 to 40 g given in divided doses over a period of 10 to 15 days.

    Acute pelvic inflammatory disease caused by N. gonorrhoeae

    500 mg Erythrocin Lactobionate-I.V. (erythromycin lactobionate for injection, USP) every 6 hours for 3 days, followed by 500 mg of erythromycin base orally every 12 hours, or 333 mg of erythromycin base orally every 8 hours for 7 days.

    Intestinal Amebiasis

    Adults

    500 mg every 12 hours, 333 mg every 8 hours or 250 mg every 6 hours for 10 to 14 days.

    Children

    30 to 50 mg/kg/day in divided doses for 10 to 14 days.

    Pertussis

    Although optimal dosage and duration have not been established, doses of erythromycin utilized in reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.

    Legionnaires' Disease

    Although optimal dosage has not been established, doses utilized in reported clinical data were 1 to 4 g daily in divided doses.

    Preoperative Prophylaxis for Elective Colorectal Surgery

    Listed below is an example of a recommended bowel preparation regimen.

    A proposed surgery time of 8:00 a.m. has been used.

    Pre-op Day 3

    Minimum residue or clear liquid diet. Bisacodyl, 1 tablet orally at 6:00 p.m.

    Pre-op Day 2

    Minimum residue or clear liquid diet. Magnesium sulfate, 30 mL, 50% solution (15 g) orally at 10:00 a.m., 2:00 p.m. and 6:00 p.m. Enema at 7:00 p.m. and 8:00 p.m.

    Pre-op Day 1

    Clear liquid diet. Supplemental (IV) fluids as needed. Magnesium sulfate, 30 mL, 50% solution (15 g) orally at 10:00 a.m. and 2:00 p.m. Neomycin sulfate (1.0 g) and erythromycin base (two 500 mg tablets, three 333 mg tablets or four 250 mg tablets) orally at 1:00 p.m., 2:00 p.m. and 11:00 p.m. No enema.

    Day of Operation

    Patient evacuates rectum at 6:30 a.m. for scheduled operation at 8:00 a.m.

  • Terbinafine Hydrochloride (Terbinafine) Tablet [Carilion Materials Management]

    Terbinafine Hydrochloride

    Terbinafine Hydrochloride (Terbinafine) Tablet [Carilion Materials Management]

    ● ●

    Fingernail onychomycosis: One 250 mg tablet once daily for 6 weeks.

    Toenail onychomycosis: One 250 mg tablet once daily for 12 weeks.

    The optimal clinical effect is seen some months after mycological cure and cessation of treatment. This is related to the period required for outgrowth of healthy nail.

  • Delzicol
    Delzicol (Mesalamine) Capsule, Delayed Release [Carilion Materials Management]

    Delzicol

    Delzicol (Mesalamine) Capsule, Delayed Release [Carilion Materials Management]

    2.1 Dosage for Treatment of Mildly to Moderately Active Ulcerative Colitis

    For adults, the recommended dosage of DELZICOL is two 400 mg capsules to be taken three times daily (total daily dose of 2.4 grams), for a duration of 6 weeks   Adults [see Clinical Studies ( )]. 14.1

    Pediatrics For pediatric patients 12 years of age and older, the recommended total daily dose of DELZICOL is weight-based (up to maximum of 2.4 grams/day). DELZICOL capsules are to be taken twice daily for a duration of 6 weeks ​ [see Clinical Studies ( )].  14.1

    Pediatric Dosage by Weight  WeightGroup (kg)  Daily Dose (mg/kg/day)  Maximum Daily Dose (grams/day)  17 to < 33  36 to 71  1.2  33 to < 54  37 to 61  2.0  54 to 90  27 to 44  2.4

    2.2 Dosage for Maintenance of Remission of Ulcerative Colitis in Adults

    For the maintenance of remission of ulcerative colitis, the recommended dose of DELZICOL in adults is 1.6 g daily, in divided doses . [see Clinical Studies ( )] 14.2

    2.3 Important Administration Instructions

    Do not open, crush, break, or chew the capsules. Swallow whole with water.

    Before prescribing DELZICOL capsules, children should be assessed for the ability to swallow capsules. DELZICOL should be dosed at least 1 hour before a meal or 2 hours after a meal.

    Two DELZICOL 400 mg capsules should not be substituted with one mesalamine delayed-release 800 mg tablet.

    2.4 Testing Prior to DELZICOL Administration

    Evaluate renal function prior to initiation of DELZICOL [see Warnings and Precautions ( )]. 5.1